{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhong S"],"funding":["Yuqin Song","Lijuan Deng"],"pagination":["541"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12896782"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(3)"],"pubmed_abstract":["<h4>Background</h4>Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphoma characterized by a poor prognosis due to high relapse rates and a lack of standardized treatment. This study aimed to evaluate the impact of induction/consolidation therapy on long-term survival and to provide extended follow-up data.<h4>Methods</h4>In this retrospective analysis, 140 immunocompetent patients with diffuse large B-cell PCNSL (DLBCL-PCNSL) treated at two centers between 2014 and 2024 were enrolled. Treatment efficacy was assessed based on baseline characteristics, therapeutic regimens, and treatment response. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and prognostic factors were identified using multivariate Cox proport"],"journal":["Cancers"],"pubmed_title":["Clinical Characteristics and Prognosis of Primary Central Nervous System Lymphoma: A Retrospective Analysis."],"pmcid":["PMC12896782"],"funding_grant_id":["Nos. 2022-1-2152, 2024-1-2151","BRWEP2024032150207","Nos. L244063, L244025","No. 82270195"],"pubmed_authors":["Ping L","Zhao L","Xie Y","Zhu J","Zhong S","Deng L","Wang X","Chai J","Mi L","Song Y"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Characteristics and Prognosis of Primary Central Nervous System Lymphoma: A Retrospective Analysis.","description":"<h4>Background</h4>Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphoma characterized by a poor prognosis due to high relapse rates and a lack of standardized treatment. This study aimed to evaluate the impact of induction/consolidation therapy on long-term survival and to provide extended follow-up data.<h4>Methods</h4>In this retrospective analysis, 140 immunocompetent patients with diffuse large B-cell PCNSL (DLBCL-PCNSL) treated at two centers between 2014 and 2024 were enrolled. Treatment efficacy was assessed based on baseline characteristics, therapeutic regimens, and treatment response. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and prognostic factors were identified using multivariate Cox proport","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-07T03:12:15.78Z","creation":"2026-07-07T03:09:41.742Z"},"accession":"S-EPMC12896782","cross_references":{"pubmed":["41682011"],"doi":["10.3390/cancers18030541"]}}